MRNA Stock Recent News

MRNA LATEST HEADLINES

MRNA Stock News Image - fool.com

In the early days of the COVID-19 pandemic, Moderna (MRNA -1.89%) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the biotech brought in billions of dollars in annual earnings and saw its stock price jump more than 2,300% from January 2020 through early August of 2021.

fool.com 2025 Apr 20
MRNA Stock News Image - zacks.com

Moderna (MRNA) reachead $24.73 at the closing of the latest trading day, reflecting a -1.85% change compared to its last close.

zacks.com 2025 Apr 17
MRNA Stock News Image - zacks.com

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

zacks.com 2025 Apr 14
MRNA Stock News Image - accessnewswire.com

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide a corporate update.

accessnewswire.com 2025 Apr 10
MRNA Stock News Image - fool.com

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%.

fool.com 2025 Apr 08
MRNA Stock News Image - accessnewswire.com

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025. Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of its research in respiratory and emerging infectious diseases.

accessnewswire.com 2025 Apr 07
MRNA Stock News Image - fool.com

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (PFE 0.77%) and Moderna (MRNA 2.21%). These two vaccine makers made small fortunes thanks to their work in this space.

fool.com 2025 Apr 03
MRNA Stock News Image - fool.com

Moderna (MRNA 2.21%) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic. Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer.

fool.com 2025 Apr 03
MRNA Stock News Image - cnbc.com

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

cnbc.com 2025 Apr 01
MRNA Stock News Image - zacks.com

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

zacks.com 2025 Apr 01
10 of 50